Agenus shared a post on LinkedIn:
“Today, Agenus announced the closing of our $141M strategic collaboration with Zydus Group; a defining milestone as we advance botensilimab + balstilimab (BOT+BAL) toward global impact.
This collaboration strengthens our balance sheet and secures committed U.S. biologics manufacturing capacity at a pivotal moment, enabling disciplined Phase 3 execution, expanded authorized paid patient access, and long-term commercial readiness.
With these foundations in place, Agenus enters 2026 focused on execution: advancing BOT+BAL through late-stage development and progressing toward regulatory submission supported by one of the most substantial clinical datasets generated in MSS colorectal cancer.
More posts about Agenus.
